257 related articles for article (PubMed ID: 36139419)
21. Growth hormone receptor blockade inhibits growth hormone-induced chemoresistance by restoring cytotoxic-induced apoptosis in breast cancer cells independently of estrogen receptor expression.
Minoia M; Gentilin E; Molè D; Rossi M; Filieri C; Tagliati F; Baroni A; Ambrosio MR; degli Uberti E; Zatelli MC
J Clin Endocrinol Metab; 2012 Jun; 97(6):E907-16. PubMed ID: 22442272
[TBL] [Abstract][Full Text] [Related]
22. Characterization of a membrane-associated estrogen receptor in breast cancer cells and its contribution to hormone therapy resistance using a novel selective ligand.
Niwa T; Takanobu J; Suzuki K; Sato Y; Yamaguchi Y; Hayashi SI
J Steroid Biochem Mol Biol; 2020 Jul; 201():105671. PubMed ID: 32289430
[TBL] [Abstract][Full Text] [Related]
23. Estrogen receptor regulation of the immune microenvironment in breast cancer.
McGuinness C; Britt KL
J Steroid Biochem Mol Biol; 2024 Jun; 240():106517. PubMed ID: 38555985
[TBL] [Abstract][Full Text] [Related]
24. Regulation of heparanase gene expression by estrogen in breast cancer.
Elkin M; Cohen I; Zcharia E; Orgel A; Guatta-Rangini Z; Peretz T; Vlodavsky I; Kleinman HK
Cancer Res; 2003 Dec; 63(24):8821-6. PubMed ID: 14695198
[TBL] [Abstract][Full Text] [Related]
25. Patient-derived luminal breast cancer xenografts retain hormone receptor heterogeneity and help define unique estrogen-dependent gene signatures.
Kabos P; Finlay-Schultz J; Li C; Kline E; Finlayson C; Wisell J; Manuel CA; Edgerton SM; Harrell JC; Elias A; Sartorius CA
Breast Cancer Res Treat; 2012 Sep; 135(2):415-32. PubMed ID: 22821401
[TBL] [Abstract][Full Text] [Related]
26. Elevated expression of FREM1 in breast cancer indicates favorable prognosis and high-level immune infiltration status.
Li HN; Li XR; Lv ZT; Cai MM; Wang G; Yang ZF
Cancer Med; 2020 Dec; 9(24):9554-9570. PubMed ID: 33058542
[TBL] [Abstract][Full Text] [Related]
27. Dynamic interactions between the extracellular matrix and estrogen activity in progression of ER+ breast cancer.
Jallow F; O'Leary KA; Rugowski DE; Guerrero JF; Ponik SM; Schuler LA
Oncogene; 2019 Oct; 38(43):6913-6925. PubMed ID: 31406251
[TBL] [Abstract][Full Text] [Related]
28. Forkhead box transcription factor FOXO3a suppresses estrogen-dependent breast cancer cell proliferation and tumorigenesis.
Zou Y; Tsai WB; Cheng CJ; Hsu C; Chung YM; Li PC; Lin SH; Hu MC
Breast Cancer Res; 2008; 10(1):R21. PubMed ID: 18312651
[TBL] [Abstract][Full Text] [Related]
29. Estrogen receptor 1 and progesterone receptor are distinct biomarkers and prognostic factors in estrogen receptor-positive breast cancer: Evidence from a bioinformatic analysis.
Wu JR; Zhao Y; Zhou XP; Qin X
Biomed Pharmacother; 2020 Jan; 121():109647. PubMed ID: 31733575
[TBL] [Abstract][Full Text] [Related]
30. Molecular Links between Central Obesity and Breast Cancer.
Zimta AA; Tigu AB; Muntean M; Cenariu D; Slaby O; Berindan-Neagoe I
Int J Mol Sci; 2019 Oct; 20(21):. PubMed ID: 31661891
[No Abstract] [Full Text] [Related]
31. Estrogen Receptor Positive Breast Cancer with High Expression of Androgen Receptor has Less Cytolytic Activity and Worse Response to Neoadjuvant Chemotherapy but Better Survival.
Okano M; Oshi M; Butash AL; Asaoka M; Katsuta E; Peng X; Qi Q; Yan L; Takabe K
Int J Mol Sci; 2019 May; 20(11):. PubMed ID: 31151151
[TBL] [Abstract][Full Text] [Related]
32. Epigenetic regulation of estrogen signaling in breast cancer.
Hervouet E; Cartron PF; Jouvenot M; Delage-Mourroux R
Epigenetics; 2013 Mar; 8(3):237-45. PubMed ID: 23364277
[TBL] [Abstract][Full Text] [Related]
33. Metabolic relevance for N-hydroxy L-arginine reduction in estrogen-negative breast cancer cells.
Mohan S; Patel S; Greenstein I; Ng C; Frazier K; Nguyen G; Harding L; Barlow D
Amino Acids; 2018 Nov; 50(11):1629-1636. PubMed ID: 29922922
[TBL] [Abstract][Full Text] [Related]
34. Molecular identification of ERalpha-positive breast cancer cells by the expression profile of an intrinsic set of estrogen regulated genes.
Weisz A; Basile W; Scafoglio C; Altucci L; Bresciani F; Facchiano A; Sismondi P; Cicatiello L; De Bortoli M
J Cell Physiol; 2004 Sep; 200(3):440-50. PubMed ID: 15254972
[TBL] [Abstract][Full Text] [Related]
35. The Many Faces of Obesity and Its Influence on Breast Cancer Risk.
Agurs-Collins T; Ross SA; Dunn BK
Front Oncol; 2019; 9():765. PubMed ID: 31555578
[TBL] [Abstract][Full Text] [Related]
36. Type I IFN stimulates IFI16-mediated aromatase expression in adipocytes that promotes E
Ka NL; Lim GY; Kim SS; Hwang S; Han J; Lee YH; Lee MO
Cell Mol Life Sci; 2022 May; 79(6):306. PubMed ID: 35593921
[TBL] [Abstract][Full Text] [Related]
37. Leptin-signaling inhibition results in efficient anti-tumor activity in estrogen receptor positive or negative breast cancer.
Rene Gonzalez R; Watters A; Xu Y; Singh UP; Mann DR; Rueda BR; Penichet ML
Breast Cancer Res; 2009; 11(3):R36. PubMed ID: 19531256
[TBL] [Abstract][Full Text] [Related]
38. Estrogen-Receptor-Low-Positive Breast Cancer: Pathological and Clinical Perspectives.
Malainou CP; Stachika N; Damianou AK; Anastopoulos A; Ploumaki I; Triantafyllou E; Drougkas K; Gomatou G; Kotteas E
Curr Oncol; 2023 Nov; 30(11):9734-9745. PubMed ID: 37999126
[TBL] [Abstract][Full Text] [Related]
39. The G Protein-Coupled Estrogen Receptor (GPER) Expression Correlates with Pro-Metastatic Pathways in ER-Negative Breast Cancer: A Bioinformatics Analysis.
Talia M; De Francesco EM; Rigiracciolo DC; Muoio MG; Muglia L; Belfiore A; Maggiolini M; Sims AH; Lappano R
Cells; 2020 Mar; 9(3):. PubMed ID: 32143514
[TBL] [Abstract][Full Text] [Related]
40. Obesity enhances nongenomic estrogen receptor crosstalk with the PI3K/Akt and MAPK pathways to promote in vitro measures of breast cancer progression.
Bowers LW; Cavazos DA; Maximo IX; Brenner AJ; Hursting SD; deGraffenried LA
Breast Cancer Res; 2013; 15(4):R59. PubMed ID: 23880059
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
